News of the WeekClinical Trials

Halt of Celebrex Study Threatens Drug's Future, Other Trials

+ See all authors and affiliations

Science  24 Dec 2004:
Vol. 306, Issue 5705, pp. 2170
DOI: 10.1126/science.306.5705.2170a

You are currently viewing the summary.

View Full Text


New research indicates Pfizer's COX-2 inhibitor Celebrex may cause increased risk of heart attacks and strokes, leading to the halting of some clinical trials involving the drug. Dozens of other COX-2 inhibitor trials are undergoing careful review. The scenario is strikingly similar to what happened this fall to Merck's COX-2 inhibitor Vioxx, which the Food and Drug Administration subsequently removed from the market.